87 related articles for article (PubMed ID: 1307973)
1. [The thrombolytic action of urokinase enhanced by prostaglandin E1 in vitro].
Ma CJ
Zhonghua Xin Xue Guan Bing Za Zhi; 1992 Dec; 20(6):355-6. PubMed ID: 1307973
[No Abstract] [Full Text] [Related]
2. Synergism of tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect.
Gurewich V; Pannell R
Thromb Haemost; 1987 Jun; 57(3):372-3. PubMed ID: 3116707
[No Abstract] [Full Text] [Related]
3. Effects of aspirin and prostaglandin E1 on in vitro thrombolysis with urokinase. Evidence for a possible role of inhibiting platelet activity in thrombolysis.
Terres W; Beythien C; Kupper W; Bleifeld W
Circulation; 1989 Jun; 79(6):1309-14. PubMed ID: 2720929
[TBL] [Abstract][Full Text] [Related]
4. In vitro potentiation of urokinase-activated lysis of human fibrin clots.
Singh K; Vézina C
J Med; 1974; 5(6):297-302. PubMed ID: 4528600
[No Abstract] [Full Text] [Related]
5. [Experimental studies on thrombolytic agents. (1) Comparison between prostaglandin E1, heparin and urokinase (author's transl)].
Suzuki T; Takano S
Nihon Ketsueki Gakkai Zasshi; 1978 Oct; 41(5):890-6. PubMed ID: 735704
[No Abstract] [Full Text] [Related]
6. The features of thrombus in a microvessel injury model and the antithrombotic efficacy of heparin, urokinase, and prostaglandin E1.
Hashimoto I; Nakanishi H; Shono Y; Yamano M; Toda M
Plast Reconstr Surg; 2003 Jun; 111(7):2307-14. PubMed ID: 12794473
[TBL] [Abstract][Full Text] [Related]
7. [A hybrid molecule of pro-urokinase and a fibrin-specific, monoclonal antibody fragment is a more effective thrombolytic agent than pro-urokinase in vitro and in vivo].
Bode C; Eberle T; Runge M; Haber E; Kübler W
Verh Dtsch Ges Inn Med; 1990; 96():1-3. PubMed ID: 2128723
[No Abstract] [Full Text] [Related]
8. Synergism of thrombolytic agents: investigational procedures and clinical potential.
Collen D
Circulation; 1988 Apr; 77(4):731-5. PubMed ID: 3127075
[No Abstract] [Full Text] [Related]
9. Tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA): potential for fibrin-specific thrombolytic therapy.
Collen D
Prog Hemost Thromb; 1986; 8():1-18. PubMed ID: 3104986
[No Abstract] [Full Text] [Related]
10. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
Matsuo O; Rijken DC; Collen D
Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
[TBL] [Abstract][Full Text] [Related]
11. Selective fibrinolytic activity of recombinant non-glycosylated human pro-urokinase (single-chain urokinase-type plasminogen activator) from bacteria.
Hanbücken FW; Schneider J; Günzler WA; Friderichs E; Giertz H; Flohé L
Arzneimittelforschung; 1987 Aug; 37(8):993-7. PubMed ID: 3118890
[TBL] [Abstract][Full Text] [Related]
12. Studies on platelet aggregation inhibitors in vivo. X. Relationship to thrombolysis.
Ambrus JL; Ambrus CM; Sharma SD; Suh OW; Gastpar H
J Med; 1982; 13(5-6):365-71. PubMed ID: 6221055
[TBL] [Abstract][Full Text] [Related]
13. [Thrombolytic agents: efficacy in relation to evolution time and dose].
García Frade LJ; Torrado MC; Loren M; Navarro JL
Rev Clin Esp; 1989 Feb; 184(2):75-9. PubMed ID: 2502822
[TBL] [Abstract][Full Text] [Related]
14. The nature of synergy between tissue-type and single chain urokinase-type plasminogen activators.
Fry ET; Mack DL; Sobel BE
Thromb Haemost; 1989 Nov; 62(3):909-16. PubMed ID: 2512679
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacology of fibrinolytics].
Klöcking HP
Z Gesamte Inn Med; 1979 Jan; 34(1):22-8. PubMed ID: 373275
[TBL] [Abstract][Full Text] [Related]
16. [Combined thrombolysis by pharmacokinetically different plasminogen activators].
Maksimenko AV
Bioorg Khim; 1998 May; 24(5):376-80. PubMed ID: 9661792
[TBL] [Abstract][Full Text] [Related]
17. [Changes in the components of the animal fibrinolytic system induced by the action of physiological activators and enzymes of fungal origin].
Andreenko GV; Serebriakova TN; Shimonaeva EE; Liutova LV; Karabasova MA
Nauchnye Doki Vyss Shkoly Biol Nauki; 1983; (3):51-4. PubMed ID: 6342687
[TBL] [Abstract][Full Text] [Related]
18. Potentiation by heparin fragment CY 222 (Choay) of thrombolysis induced by human tissue-type plasminogen activator.
Juhan-Vague I; Stassen JM; Alessi MC; Elias A; Aillaud MF; Serradimigni A; Collen D
Semin Thromb Hemost; 1989 Oct; 15(4):390-4. PubMed ID: 2554499
[No Abstract] [Full Text] [Related]
19. Problems of thrombolytic therapy.
Neilson RF; Davidson JF
Adverse Drug React Toxicol Rev; 1996 Mar; 15(1):51-64. PubMed ID: 8920633
[No Abstract] [Full Text] [Related]
20. [Thrombolytics and their use].
Alessi MC; Juhan-Vague I
Rev Prat; 1999 Oct; 49(15):1654-8. PubMed ID: 10581996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
